Sep 2026· Natural Resources for Human Health· 0 citations· 26 references
TL;DR
SGLT2 inhibitor uptake increased substantially during early adoption among medication-treated adults with type 2 diabetes mellitus from 2013 to 2018, and the findings characterize prescribing patterns and prevalent health profiles rather than causal treatment effects.
Abstract
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes in randomized trials, but their early use and the cardiovascular profile of users in the United States population remain less clearly described.Methods: This cross-sectional study examined current SGLT2 inhibitor use and cardiovascular health among medication-treated adults with type 2 diabetes mellitus using National Health and Nutrition Examination Survey data from 2013 to 2018. Prescription records identified current use. The primary outcome was self-reported cardiovascular disease, defined as a history of congestive heart failure, coronary heart disease, angina, myocardial infarction, or stroke. Survey-weighted logistic and linear regression incorporated the complex sampling design and adjusted for demographic and clinical covariates.Results: Among 1,978 eligible participants, 57 used an SGLT2 inhibitor. Weighted use increased from 0.5% in 2013 to 2014 to 7.1% in 2017 to 2018 and was 3.7% across the pooled period. Users were younger, had shorter diabetes duration, and had higher estimated glomerular filtration rate than nonusers. Weighted cardiovascular disease prevalence was 34.1% among users and 28.3% among nonusers. The fully adjusted odds ratio was 1.66 (95% confidence interval, 0.72 to 3.87; p = .231). Adjusted differences in blood pressure, body mass index, glycated hemoglobin, and lipid measures were imprecise, and sensitivity analyses did not materially alter the primary estimate.Conclusion: SGLT2 inhibitor uptake increased substantially during early adoption. The findings characterize prescribing patterns and prevalent health profiles rather than causal treatment effects because medication use and cardiovascular history were measured concurrently.
Evaluating the cardiometabolic effectiveness and safety of SGLT2 inhibitors among adults with T2DM and cardiovascular risk factors in routine clinical practice may help characterize their clinical pharmacology and pharmacovigilance profile in a tertiary-care medical-college setting.
Anand, A. Mittal, M. Kaushik et al.· Adolescência e Saúde· 0 citations
SGLT-2 inhibitors and GLP-1 receptor agonists form an effective strategy for managing MetS in the context of T2DM and their broad effects on metabolism and well-known heart and kidney benefits make them vital parts of modern treatment for cardiometabolic conditions.
Hadeeqah Zayaan Riaz Ahamed, Sulthan Al Rashid, Rajkapoor Balasubramanian et al.· Cardiovascular & Haematologi...· 0 citations
AIMS
Cardioprotective glucose-lowering drugs (GLDs) remain underutilised in individuals with Type 2 diabetes (T2D) and cardiovascular disease (CVD). We aimed to estimate the association between sex and socioeconomic status and initiation of cardioprotective GLDs and to identify factors associated with non-initiation of...
E. Calderon, L. Bjerg, A. Isaksen et al.· Diabetes, obesity and metabo...· 0 citations
These findings support proactive, guideline-concordant initiation of evidence-based SGLT2i agents by endocrinologists, cardiologists and primary care providers as foundational therapy in type 2 diabetes mellitus.
Ahmed Elbataa, A. Mansour, Ahmed Elazab et al.· Diabetes, obesity and metabo...· 0 citations
Research on the association between sodium‑glucose cotransporter 2 inhibitors (SGLT-2i) and chronic lower respiratory diseases (CLRDs) in patients with type 2 diabetes (T2DM) remains limited. This study aimed to investigate this association and examine the potential modifying effects such as age, sex, and diabete...
Yu-Hao Li, Yiqiao Lv, Yong-Qi Dai et al.· Respiratory Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.